UT Health San Antonio Multispecialty and Research Hospital says it’s the first in Texas to add a new non-opioid medication to ...

Delivered as a once-daily 30 mg/mL IV bolus injection over 15 seconds, Xifyrm can be used alone or alongside non-NSAID ...

The deal tees up a pain treatment market rivalry with Vertex Pharmaceuticals as the industry starts to move away from opioids.

CenExel Celebrates FDA Approval of JOURNAVX(TM), a Groundbreaking Non-Opioid Pain Treatment ACCESSWIRE. Updated February 06, 2025 12:17 PM.

With JOURNAVX's approval, physicians now have a new, non-opioid treatment option that delivers effective relief without the risk of dependency, helping to reshape the acute pain treatment landscape.

The FDA approved Journavx on Thursday following a pair of clinical trials on 874 participants with moderate to severe acute pain following abdominoplasty — commonly known as a "tummy tuck ...

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.. The active ingredient in Journavx is suzetrigine, a ...

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller to win FDA approval in more than 20 years.

The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.

The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025. Journavx is ...

Vertex plans to charge a wholesale price of $15.50 per 50-mg pill for Journavx, and the U.S. FDA approval in the acute pain indication could also bode well for winning future approval for the drug ...